Global Liver Disease Treatment Market 2017-2021

肝疾患治療薬の世界市場2017-2021

◆タイトル:Global Liver Disease Treatment Market 2017-2021
◆商品コード:IRTNTR13713
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年7月19日
◆ページ数:98
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、肝疾患治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、肝疾患治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

肝臓は、損傷を受けても完全に回復することができる、身体の中でもっとも大きな臓器です。しかしながら、長い間治療を受けずに肝臓に負担をかけ続ける事は、死につながることもあります。ウイルス性肝炎は世界中の多くの人々が罹患している肝臓の主な病気の一つですが、ウイルスの感染によるものであり、汚染された食料や水を通じて広まります。Technavio社は肝疾患治療薬の世界市場が2017-2021年期間中に年平均11.01%成長すると予測しています。当レポート上に記載されている主な企業は• F. Hoffmann-la Roche• Gilead• GlaxoSmithKline• Merck等です。

About Liver Disease TreatmentLiver is the largest organ of the body and can completely recover from damage. However, continuous strain on the liver, when treatment is delayed, for a prolonged period of time can lead to severe damage to the liver and can even be fatal.
Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as India and China has led to a higher prevalence of the disease in these countries. There has been a rise in healthcare investment in these countries.
Technavio’s analysts forecast the global liver disease treatment market to grow at a CAGR of 11.01% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global liver disease treatment market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs in liver disease treatment market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Liver Disease Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-la Roche
• Gilead
• GlaxoSmithKline
• Merck

[Other prominent vendors]
• Bristol-Myers Squibb

• Johnson and Johnson
• Novartis
• Salix Pharmaceuticals
• Vertex Pharmaceuticals

[Market driver]
• Increase in alcohol-related liver disease
• For a full, detailed list, view our report

[Market challenge]
• Side-effects of liver disease treatment drugs
• For a full, detailed list, view our report

[Market trend]
• Rise in awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Drug class segmentation
• Global liver disease treatment market by anti-viral drugs
• Global liver disease treatment market by corticosteroids
• Global liver disease treatment market by other drugs
• Global liver disease treatment market by vaccines

PART 08: Market segmentation by disease type
• ARLD
• NAFLD
• Hepatitis
• PBC
• Hemochromatosis

PART 09: Geographical segmentation
• Liver disease treatment market in Americas
• Liver disease treatment market in EMEA
• Liver disease treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Rise in awareness
• Increase in R&D activities for liver cirrhosis medication
• Increasing collaborations and M&A

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• F. Hoffmann-la Roche
• Gilead
• GlaxoSmithKline
• Merck
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Functions of liver
Exhibit 02: Types of liver diseases
Exhibit 03: Global liver disease treatment market
Exhibit 04: Global liver disease treatment market 2016-2021 ($ billions)
Exhibit 05: Opportunity analysis of global liver disease drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline summary based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global liver disease market by drug class
Exhibit 10: Global liver disease treatment market by drug class 2016 and 2021
Exhibit 11: Global liver disease treatment market by anti-viral drugs 2016-2021 ($ billions)
Exhibit 12: HIV treatment regimen approved by FDA
Exhibit 13: Global liver disease treatment market by corticosteroids 2016-2021 ($ billions)
Exhibit 14: Global liver disease treatment market by other drugs 2016-2021 ($ billions)
Exhibit 15: Global liver disease treatment market by vaccines 2016-2021 ($ billions)
Exhibit 16: Vaccination coverage for birth dose of hepatitis B vaccine in various regions 2013
Exhibit 17: Vaccination coverage for three doses of hepatitis B vaccine in various regions 2013
Exhibit 18: Global liver disease treatment market by disease type
Exhibit 19: Stages of ARLD
Exhibit 20: Deaths due to ARLD in US 2014
Exhibit 21: Stages of NAFLD
Exhibit 22: Types of hepatitis
Exhibit 23: Mode of transmission and incubation period of different types of hepatitis
Exhibit 24: Hepatitis A: Key marketed drugs
Exhibit 25: Hepatitis B: Key marketed drugs
Exhibit 26: Hepatitis C: Key marketed drugs
Exhibit 27: Medications for symptoms of PBC
Exhibit 28: Global liver disease treatment market by geography 2016 and 2021
Exhibit 29: Global liver disease treatment market by geography 2016-2021 ($ billions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Liver disease treatment market in Americas 2016-2021 ($ billions)
Exhibit 32: Factors contributing to liver cancer in US
Exhibit 33: Hepatitis infection scenario in US, 2015-2016
Exhibit 34: Market scenario in EMEA
Exhibit 35: Liver disease treatment market in EMEA 2016-2021 ($ billions)
Exhibit 36: Market scenario in APAC
Exhibit 37: Liver disease treatment market in APAC 2016-2021 ($ billions)
Exhibit 38: Top Asian countries in terms of population with diabetes
Exhibit 39: Countries with large populations without adequate sanitation 2014
Exhibit 40: Effects of lifestyle diseases on liver
Exhibit 41: Competitive structure analysis of global liver disease treatment market 2016
Exhibit 42: Strategic success factors of companies in global liver disease treatment market
Exhibit 43: F. Hoffmann-la Roche: Key highlights
Exhibit 44: F. Hoffmann-la Roche: Strength assessment
Exhibit 45: F. Hoffmann-la Roche: Strategy assessment
Exhibit 46: F. Hoffmann-la Roche: Opportunity assessment
Exhibit 47: Gilead: Key highlights
Exhibit 48: Gilead: Strength assessment
Exhibit 49: Gilead: Strategy assessment
Exhibit 50: Gilead: Opportunity assessment
Exhibit 51: GlaxoSmithKline: Key highlights
Exhibit 52: GlaxoSmithKline: Strength assessment
Exhibit 53: GlaxoSmithKline: Strategy assessment
Exhibit 54: GlaxoSmithKline: Opportunity assessment
Exhibit 55: Merck: Key highlights
Exhibit 56: Merck: Strength assessment
Exhibit 57: Merck: Strategy assessment
Exhibit 58: Merck: Opportunity assessment



【掲載企業】

F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, ristol-Myers Squibb, Johnson and Johnson, Novartis, Salix Pharmaceuticals, and Vertex Pharmaceuticals.

★調査レポート[肝疾患治療薬の世界市場2017-2021] (Global Liver Disease Treatment Market 2017-2021 / IRTNTR13713)販売に関する免責事項
[肝疾患治療薬の世界市場2017-2021] (Global Liver Disease Treatment Market 2017-2021 / IRTNTR13713)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆